Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
OSE Immunotherapeutics and Boehringer Ingelheim Extend Their Collaboration to Develop First-in-class Treatments in Cancer and Cardiovascular, Renal and Metabolic Diseases
Thursday, May 23, 2024OSE Immunotherapeutics SA and Boehringer Ingelheim today announce a major expansion of their collaboration Two new projects aimed at developing firstinclass
Genmab Completes Acquisition of ProfoundBio
Wednesday, May 22, 2024Genmab AS announced today that it has completed its acquisition of ProfoundBio Inc a clinicalstage biotechnology company developing nextgeneration antibody drug conjugates and ADC technologies for the treatment of cancers in an allcash transaction of...
Asymchem to Operate Development and Manufacturing Facilities at Former Pfizer API Pilot Plant in Sandwich (UK)
Wednesday, May 22, 2024Asymchem Laboratories Co Ltd today announced that it will operate Pfizer UKs former small molecule API pilot plant as well as part of its development laboratories in as part of a new lease agreement between Asymchem
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
Tuesday, May 21, 2024Coya Therapeutics Inc a clinicalstage biotechnology company developing biologics intended to enhance regulatory T cell function announces that the Alzheimers Drug Discovery
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
Tuesday, May 21, 2024GigaGen Inc a biotechnology company advancing transformative antibody drugs for immune deficiencies infectious diseases and checkpoint resistant cancers and a subsidiary of Grifols announced today that the first patient
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
Monday, May 20, 2024ERS Genomics Limited the CRISPR licensing Company and IRBM a leader in the field of drug discovery today announced a nonexclusive CRISPRCas license agreement The agreement grants IRBM access to ERS CRISPRCas patent
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Saturday, May 18, 2024Marinus Pharmaceuticals Inc a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders today announced completion of enrollment in the global
FDA Approves IMDELLTRA™ (Tarlatamab-dlle), the First and Only T-cell Engager Therapy for the Treatment of Extensive-stage Small Cell Lung Cancer
Friday, May 17, 2024Amgen today announced that the US Food and Drug Administration has approved IMDELLTRA for the treatment of adult patients with extensivestage small cell lung
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Friday, May 17, 2024Tourmaline Bio Inc a latestage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Thursday, May 16, 2024Oncolytics Biotech Inc a leading clinicalstage company specializing in immunotherapy for oncology today announced that it has entered
